New and updated preclinical and clinical data presented by biopharma firms at IDWeek 2021, including: Allovir, Codagenix, Ferring, Humanigen, Iliad, Mycovia, Neoleukin, Peptilogics, Scynexis, Seqirus, Viiv.
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Aprea, Redx, Syros.
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Astellas, Astrazeneca, Beyondspring, Byondis, Carsgen, Cstone, Daiichi, Exelixis, Genentech, Genmab, GT, Innovent, Immunocore, Ipsen, Janssen, Merck, Mirati, Novartis, Ose, Regeneron, Sanofi, Spectrum, Verastem, Veru.
Despite Beyondspring Pharmaceuticals Inc.’s phase III study meeting its primary and key secondary endpoints of a plinabulin/docetaxel combination in treating non-small-cell lung cancer (NSCLC), the company stock (NADAQ:BYSI) took a pounding. Shares sunk 32.9% on Sept. 20 to close at $15.36 each.
Monoclonal antibodies are already a pillar of cancer therapy, and cancer makes up the largest indication of FDA-approved antibodies, with almost 40% of the total. At the 2021 European Society of Medical Oncology (ESMO) Congress, Elena Garralda predicted that engineered versions of classical antibodies will soon join them on their pedestal.
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Agenus, Alpha Cancer, Astrazeneca, Boehringer, Bridge, Corcept, Daiichi, Deciphera, Eqrx, Gritstone, Imcheck, Janssen, Junshi, Novartis, Tachyon, TCR2, Tilt.
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Acepodia, Aileron, Allarity, Amgen, Athenex, Ayala, Bayer, Beyondspring, Bioxcel, Carrick, Exelixis, Gilead, Instil, Laekna, Leap, Macrogenics, Medigene, Medivir, NGM, Nouscom, Oncologie, Psioxus, Second Genome, Shasqi, Silverback, Targovax, Transgene, Zymeworks.
The European Society for Medical Oncology Congress 2021 has begun with a mix of education and multidisciplinary sessions in addition to symposia. Silverback Therapeutics Inc. was a presenter and took a hit on the market Sept. 16 with its interim phase I/Ib study results showing SBT-6050’s proof of mechanism was established with activated myeloid and T/natural killer cells when treating advanced or metastatic HER2-expressing solid tumors.
DUBLIN – Allarity Therapeutics A/S plans to file an NDA with FDA for dovitinib in renal cell carcinoma (RCC) in the fourth quarter this year, after unveiling a new analysis at the European Society for Molecular Oncology’s virtual congress, which suggest that its companion diagnostic, DRP, can identify patients who obtain a survival benefit from the therapy.
New and updated preclinical and clinical data to be presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Adaptimmune, Boehringer Ingelheim, BMS, Cantargia, Harbour, Leap, Ose, Samsung Bioepis, Zymeworks.
RSS
